Alle Storys
Folgen
Keine Story von Isotechnika Inc. mehr verpassen.

Isotechnika Inc.

Isotechnika Inc. Appoints International Pharmaceutical Business Leader to Board of Directors

Edmonton, Alberta (ots/PRNewswire)

Isotechnika Inc. announced
today the appointment of Patrice R.  Debregeas to its board of
directors. As Chairman, CEO and President of  Ethypharm S.A, the
leading drug delivery company in Europe, Mr. Debregeas  brings
extensive international experience in the pharmaceutical sector.
Under the supervision of Mr. Debregeas, Ethypharm has successfully
launched 50 products in over 70 countries.
Mr. Debregeas holds an MBA from Wharton Graduate School of
Business at  the University of Pennsylvania and an M.S. in Pharmacy
from the University  of Paris. "I am most excited to be joining the
Board of Directors for  Isotechnika Inc., a Company that is
developing a very strong pipeline of  therapeutic products and a new
test for insulin resistance that could  change the diagnosis of
diabetic patients worldwide," stated Mr. Debregeas.
"It is both a pleasure and a privilege to welcome Patrice
Debregeas to  our board of directors," stated Dr. Robert Foster,
Isotechnika's Chairman  and CEO. "Mr. Debregeas' years of experience
in the delivery of  pharmaceutical products will be a valuable asset
as our lead drug candidate , ISA247 advances towards a Phase III
psoriasis trial later this year."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in  medicinal chemistry and immunology, the Company is
focused on the discovery  and development of novel immunosuppressive
therapeutics that are safer than  currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug  candidates for use in
the prevention of organ rejection in transplantation  and in the
treatment of autoimmune diseases. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as
trans-ISA247,  is an immunosuppressant that has successfully
completed a Phase II trial  for psoriasis and Phase IIa trial for
kidney transplantation. Isotechnika  recently expanded its product
pipeline by developing two additional novel  immunosuppressive
compounds, TAFA93 and TKB662. TAFA93 is a novel small  molecule mTOR
inhibitor, a class of drugs currently used in the prevention  of
organ rejection in transplantation and as a coated stent therapy in
the  treatment of coronary artery disease. Pre-clinical studies of
TKB662 have  demonstrated inhibition of T cell and B cell activation
and proliferation  through multiple mechanisms of action including
the inhibition of  lymphocyte phosphorylation activity. As both
TAFA93 and TKB662 have  distinct mechanisms of action from
calcineurin inhibitors such as ISA247  they have the potential to be
administered as complementary therapies in  both prevention of organ
rejection and treatment of autoimmune diseases.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(TM) and Diatest(TM)
breath  kits. The Helikit(TM), a (13)C breath test is used for the
detection of H. pylori, a bacterium that infects a large portion of
the population. The  Helikit(TM) is currently sold internationally.
The Diatest(TM), a (13)C  glucose breath test is used for the
detection of insulin resistance. The  Company expects to commence the
necessary clinical trials in 2005 involving  the Diatest(TM) to
obtain regulatory approval in the United States.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its  intellectual property, involve known and unknown risks and
uncertainties,  which could cause the Company's actual results to
differ materially from  those in the     forward-looking statements.
Such risks and uncertainties  include, among others, the availability
of funds and resources to pursue  research and development projects,
the ability to economically manufacture  its products, the potential
of its products, the success and timely  completion of clinical
studies and trials, the Company's ability to  successfully
commercialize its products, the ability of the Company to  defend its
patents from infringement by third parties, and the risk that  the
Company's patents may be subsequently shown to be invalid or infringe
the patents of others. Investors should consult the Company's
quarterly and  annual filings with the Canadian commissions for
additional information on  risks and uncertainties relating to the
forward-looking statements.  Investors are cautioned against placing
undue reliance on forward-looking statements.
Archived images on this organization are available through CNW
E-Pix at  http://www.newswire.ca. Images are free to members of The
Canadian Press.  To request a free copy of this organization's annual
report, please go to http://www.newswire.ca and click on reports@cnw.

Contact:

For further information: Dr. Robert Foster, Chairman & CEO,
Isotechnika Inc., +1(780)-487-1600 ext. 246, +1(780)-484-4105 (fax),
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Manager,
Corporate Communications, Isotechnika Inc., +1(780)-487-1600 ext.
243, +1(780)-484-4105 (fax), sgillis-paulgaard@isotechnika.com

Weitere Storys: Isotechnika Inc.
Weitere Storys: Isotechnika Inc.
  • 09.09.2004 – 14:06

    Isotechnika Inc. Reports Interim Results of QTc Trial

    Edmonton, Alberta, Canada (ots/PRNewswire) - Isotechnika Inc. announced today they have received the interim results of the QTc trial for its lead immunosuppressive drug, ISA247 from eResearch Technology Inc. The study, conducted by Pracs in Fargo, North Dakota was designed as a double blind, parallel group, placebo and moxifloxacin controlled, randomized, single dose QTc study of trans-ISA247 in healthy volunteers. In ...

  • 07.07.2004 – 14:03

    FDA Grants Permission to Isotechnika for TAFA-93 Clinical Trial

    EDMONTON, Canada, July 7 (ots/PRNewswire) - Isotechnika Inc. today announced that the Company has received permission from the Food and Drug Administration of the United States for the commencement of a Phase Ib human clinical trial for TAFA-93. TAFA-93 is a novel prodrug of the mTOR inhibitor rapamycin designed to reduce the unfavourable pharmacokinetics ...

  • 06.07.2004 – 14:13

    Positive Data From Trans-ISA247 Single Ascending Dose Trial

    EDMONTON, Canada, July 6 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today the completion of the single ascending dose trial for the Company's lead immunosuppressive drug candidate, ISA247. The SAD trial was conducted in healthy volunteers using the trans-ISA247 formulation to assess the appropriate dosage of the enhanced composition of the drug. The data confirms that the trans formulation of ...